Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07703163RecruitingPhase 1
Canagliflozin for advanced solid tumors in patients with or without diabetes
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
Chengdu, SichuanAges 18–80 - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT07683195Enrolling by invitation
Using CT scans to predict early stomach cancer return
This study uses information from CT scans done before stomach cancer surgery to see if it can predict whether the cancer may come back early. Researchers want to find patterns in the scans that might help doctors plan better follow-up care.
Jinan, ShandongAges 18–85 - NCT06288373RecruitingPhase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hefei, AnhuiAges 18–70 - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07638436RecruitingPhase 2
Immunotherapy with chemotherapy for advanced esophageal cancer
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07632079RecruitingPhase 2
Fast-Track Radiation and Chemotherapy for Esophageal Cancer
This study tests a shorter course of combined radiation therapy and chemotherapy (using drugs called paclitaxel and carboplatin) to treat esophageal cancer with the goal of curing it. The faster treatment schedule may help patients finish therapy sooner while still being effective.
AmsterdamAges 18 years+ - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07622771RecruitingPhase 2
Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06444009RecruitingPhase 2
Immunotherapy and chemo before surgery for head and neck cancer
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Chengdu, SichuanAges 18–75 - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07586124RecruitingPhase 2
Immunotherapy plus antibody drug for advanced head and neck cancer
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT07559045RecruitingPhase 2
Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Zunyi, GuizhouAges 18–75 - NCT06689540RecruitingPhase 1
MTS105 for advanced liver cancer with GPC3
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
BeijingAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06054906RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
ShanghaiAges 18 years+ - NCT07532928Enrolling by invitation
Personalized Post-Surgery Care Plan for Advanced Head and Neck Cancer
This study helps doctors create a personalized plan for follow-up treatment after surgery for advanced head and neck cancer. Researchers will use imaging scans and patient data to predict which patients need extra treatment and which ones can be monitored closely instead.
GuangzhouAges 18 years+ - NCT06202105Recruiting
Laparoscopic vs open total gastrectomy for advanced stomach cancer
This trial compares two types of surgery for stomach cancer that has grown into deeper layers but has not spread to distant organs. The goal is to see if a keyhole (laparoscopic) approach is as safe and effective as traditional open surgery.
Bien Hoa, Dong NaiAges 18–80 - NCT07524140RecruitingPhase 1
Study of ZE94-0605 for advanced solid tumors
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Kogarah, New South WalesAges 18 years+ - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,511 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.